Tumor cells exploit G-protein-coupled receptor (GPCR) signaling networks to promote angiogenesis, grow and metastasize. We show that tumor cells leverage a GPCR–Gαs–protein kinase A (PKA) signaling axis to polarize CD8+ T cells into a dysfunctional state, thereby limiting the tumor infiltration and cytotoxic function of these cells and reducing the efficacy of current immunotherapies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
N6-methyladenosine-modified circSLCO1B3 promotes intrahepatic cholangiocarcinoma progression via regulating HOXC8 and PD-L1
Journal of Experimental & Clinical Cancer Research Open Access 20 April 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Haslam, A. & Prasad, V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw. Open 2, e192535 (2019). An article that examines the responses of patients with cancer to checkpoint inhibitor immunotherapies in the USA
Wu, V. et al. Illuminating the Onco-GPCRome: novel G protein-coupled receptor-driven oncocrine networks and targets for cancer immunotherapy. J. Biol. Chem. 294, 11062–11086 (2019). A computational analysis highlighting the widespread GPCR–G-protein alterations in tumor biology, and opportunities for new drug targets in cancer immunotherapy.
Inoue, A. et al. Illuminating G-protein-coupling selectivity of GPCRs. Cell 177, 1933–1947 e1925 (2019). A study that systematically examines ligand-induced interactions between GPCRs and distinct G-protein subunits and the use of machine learning approaches to predict GPCR–G-protein coupling specificity.
Urban, D. J. & Roth, B. L. DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility. Annu. Rev. Pharmacol. Toxicol. 55, 399–417 (2015). A review article that presents advances in the use of chemogenetic approaches to investigate the role of GPCRs in physiology, disease and translational settings.
Ayers, M. et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Investig. 127, 2930–2940 (2017). A study that identifies an immune-related gene expression profile involving the CXCR3–CXCL9, CXCR3–CXCL10 and CXCR3–CXCL11 axes that correlates with clinical responses to anti-PD1 immunotherapy.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Wu, V. H. et al. The GPCR–Gαs–PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure. Nat. Immunol. https://doi.org/10.1038/s41590-023-01529-7 (2023).
Rights and permissions
About this article
Cite this article
A GPCR checkpoint drives CD8+ T cell dysfunction and immunotherapy failure in mice. Nat Immunol 24, 1232–1233 (2023). https://doi.org/10.1038/s41590-023-01567-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-023-01567-1
This article is cited by
-
N6-methyladenosine-modified circSLCO1B3 promotes intrahepatic cholangiocarcinoma progression via regulating HOXC8 and PD-L1
Journal of Experimental & Clinical Cancer Research (2024)
